Navigation Links
Investigational New Drug Application for 'Fat Melting' Injections Cleared by the FDA
Date:9/4/2007

Clinical trial on injection lipolysis treatment to begin soon

NEW YORK, Sept. 4 /PRNewswire-USNewswire/ -- The Aesthetic Surgery Education and Research Foundation (ASERF) announced today that it has received approval from the U.S. Food and Drug Administration to initiate a clinical trial investigating the safety and efficacy of one type of injection lipolysis treatment.

Treatments most properly called injection lipolysis have been commonly associated with the terms mesotherapy or fat dissolving "Lipodissolve." These types of treatments claim to reduce or eliminate unwanted local accumulations of fat, but their ingredients and injection locations and techniques may vary slightly. There is also no standardized, consistent, and accepted injection protocol or chemical formulation, with many formulas being proprietary, and without scientifically valid studies documenting their safety or effectiveness or comparing one another. Injection lipolysis involves the injection of various compounds into the subcutaneous fat, but is not currently approved by the FDA for subcutaneous injection for any purpose.

"We are pleased to finally have the approval to move forward on this important clinical trial," said V. Leroy Young, MD, chief investigator for the study. "This study is long overdue, and will go a long way toward developing more standardized protocols and ultimately improving patient safety in this area."

The study, which was designed and funded by ASERF, will be conducted under FDA supervision and will follow patients for 46 weeks to evaluate the efficacy of one form of injection lipolysis and collect data on local and systemic reactions and any long-term complications. The study will include imaging, biochemical analysis and clinical measurements for objective evaluation of the efficacy and safety of the treatment.

"Although there are clinical reports of significant and positive results, they are all anecdotal, and unfortunately ther
'/>"/>

SOURCE Aesthetic Surgery Education and Research Foundation
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. New Drug Application Submitted for Investigational Antibiotic Doripenem
2. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
3. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
4. Novel Investigational Drug May Help American Women Suffering from Breast Pain
5. Novartis files application with FDA for Zometa
6. Morepan to file new drug applications with the USFDA
7. Mini motor for micromedical applications
8. Perfusion bioreactor could enhance stem cell research and application in the future
9. Prostate Cancer Can Be Treated By Application Of LASER Technology
10. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
11. Venus Remedies Files 5th International Patent Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...ire/ -- Susan Knapp Pinnas, a leader of provider,... diversified healthcare,experience, has been name...e,company announced today. , As a member o... be,responsible for advancing AvMed,s overall pro...of strong relationships and service excellence. P...
(Date:1/8/2009)...and Education Act Mandates Label Accuracy, Truth i...GTON, Jan. 8 In respons... dietary supplement regulation, the Natural Produc... Seckman, released this statement: , , Increase...id usage, which the Natural Products Association (...
(Date:1/8/2009)...fficials Expect to Maintain or Increase Spending A... Roads and Bridges, Creation of 21st Century Schoo...ent Facilities , , SEATTLE, Jan. 8 /PRNewswire-...mic stimulus package outlines a significant increa...ion of roads and bridges, 21st-century school proj...
(Date:1/8/2009)...likely to be deadly for women and African-American...enomenon account for only part of the differences ... counterparts, according to results published in t...esults present a stark question for doctors and pa...se upon diagnosis don,t account for all the increa...
Breaking Medicine News(10 mins):Health News:Susan Knapp Pinnas Named AvMed Health Plans' New Senior Vice President of Network 2Health News:Natural Products Association Advocates Strength of Dietary Supplement Law 2Health News:Government at all Levels Will Continue to Spend on Essential Services and Invest in the Future, According to Onvia Study 2Health News:Government at all Levels Will Continue to Spend on Essential Services and Invest in the Future, According to Onvia Study 3Health News:Government at all Levels Will Continue to Spend on Essential Services and Invest in the Future, According to Onvia Study 4Health News:Why bladder cancer is deadlier for some 2Health News:Why bladder cancer is deadlier for some 3Health News:Why bladder cancer is deadlier for some 4
...nown as ReVia, is an approved drug for the treatme...with the drug is it is taken orally, which can red...ifferently in the body. A new study looks at an in...f its use for alcoholics. For the study 315 alcoh...
...a history of an ischemic stroke, which is a stroke... clopidogrel. // However, new research shows this ...stroke. Researchers conducted a study to see if ad...patients would be beneficial as it is in heart dis...
... Taiwan suggests drinking tea may keep your blood ...now discovered // that people who drank between 12...ng tea a day for a year had a 46-percent decreased...id not drink tea regularly. People who consumed mo...
...success reducing pain in patients with multiple sc...abinol, also known as Marinol, has been used to so...rs evaluated the effect of Dronabinol on pain in p...ents with multiple sclerosis and central pain par...
Other Medicine News:
(Date:1/6/2009)...Jan. 6 The Michael J. F...n to four industry research teams for pre-clinical...n,s disease. , , The funding was awarded under ...ive. This program, first launched in 2006, suppor...son,s research. TDI is part of MJFF,s focus on ...
(Date:1/6/2009)... France, January 6 , ... Collaboration Until,December 2011 , - Exp...e Antibody,Discovery in Ophthalmology , - ...f Allergan,Sublicenses to a Third Party , ...nounced a reinforcement,of its existing drug disc...
(Date:1/3/2009)... , , ROSEMONT, Ill., Jan. 2 /PRNewswi... is a growing technology providing an increasing n...tion of back pain according to an article in the J...cademy of Orthopaedic Surgeons ( http://www.jaaos....l years, additional technical developments will al...
(Date:12/27/2008)...MAS, Calif., Dec. 27 According to ...st advised to consume modest doses of,resveratrol...ly provided in 3,to 5 glasses of aged, red wine, ...http://www.newscom.com/cgi-bin/prnh/20080603/LATU0...se resveratrol alone fails to prolong,the life of...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines 7712 1Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines 7712 2Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model 7710 1Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model 7710 2Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model 7710 3Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model 7710 4Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model 7710 5NIEHS invests 2421 25 million to find environmental causes of Parkinsons disease 4906 1NIEHS invests 2421 25 million to find environmental causes of Parkinsons disease 4906 2NIEHS invests 2421 25 million to find environmental causes of Parkinsons disease 4906 3Expert urges FDA to take action to reduce BPA exposure 4904 1Expert urges FDA to take action to reduce BPA exposure 4904 2
...ng,poliomyelitis from the remaining infected count... than the long term costs of trying,to control inf...ped,monovalent vaccine is almost three times more ...sting trivalent vaccine. These are,the findings of...issue of The Lancet. , Both Articles look at the s...
...), a,biopharmaceutical company specializing in dev...Lipoprotein (HDL), often called,"good cholesterol,...s of the Phase I/II Clinical Trial of its lead pro...ent of dyslipidemia and,heart disease. , A detaile...,blood chemistry and blood pressure measurements w...
Other Medicine Technology:Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 2Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 3Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical,Trial Data 2Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical,Trial Data 3
The OraQuick ADVANCE Rapid HIV-1/2 Antibody Test is a single-use, qualitative immunoassay to detect antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2) in oral fluid, fingers
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple
Standard Trephine
Coronet Vacuum Trephine - All metal, ergonomic design and ultra sharp blade with cross hairs.
Medicine Products: